229 related articles for article (PubMed ID: 11335185)
1. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.
Ladona MG; Izquierdo-Martinez M; Posada de la Paz MP; de la Torre R; Ampurdanés C; Segura J; Sanz EJ
Environ Health Perspect; 2001 Apr; 109(4):369-75. PubMed ID: 11335185
[TBL] [Abstract][Full Text] [Related]
2. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
5. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly AK; Cholerton S; Armstrong M; Idle JR
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
[TBL] [Abstract][Full Text] [Related]
6. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays.
Zhao B; Lee EJ; Wong JY; Yeoh PN; Gong NH
Pharmacogenetics; 1995 Oct; 5(5):275-80. PubMed ID: 8563767
[TBL] [Abstract][Full Text] [Related]
7. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Sachse C; Smith G; Wilkie MJ; Barrett JH; Waxman R; Sullivan F; Forman D; Bishop DT; Wolf CR;
Carcinogenesis; 2002 Nov; 23(11):1839-49. PubMed ID: 12419832
[TBL] [Abstract][Full Text] [Related]
8. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
10. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Mota P; Silva HC; Soares MJ; Pego A; Loureiro M; Cordeiro CR; Regateiro FJ
J Cancer Res Clin Oncol; 2015 May; 141(5):851-60. PubMed ID: 25388590
[TBL] [Abstract][Full Text] [Related]
13. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias.
Lemos MC; Cabrita FJ; Silva HA; Vivan M; Plácido F; Regateiro FJ
Carcinogenesis; 1999 Jul; 20(7):1225-9. PubMed ID: 10383893
[TBL] [Abstract][Full Text] [Related]
15. N-Acetyltransferase 2 polymorphism in patients with Spanish toxic oil syndrome.
Ladero JM
Environ Health Perspect; 2002 Jan; 110(1):A14. PubMed ID: 11813699
[No Abstract] [Full Text] [Related]
16. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW; Commandeur JN; Vermeulen NP
Crit Rev Toxicol; 1999 Jan; 29(1):59-124. PubMed ID: 10066160
[TBL] [Abstract][Full Text] [Related]
17. Association of cytochrome P450, glutathione S-transferase and N-acetyl transferase 2 gene polymorphisms with incidence of acute myeloid leukemia.
Majumdar S; Mondal BC; Ghosh M; Dey S; Mukhopadhyay A; Chandra S; Dasgupta UB
Eur J Cancer Prev; 2008 Apr; 17(2):125-32. PubMed ID: 18287869
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the polymorphic alleles of genes encoding phase 1 and phase 2 detoxication enzymes in patients with endometriosis].
Ivashchenko TE; Shved NIu; Kramareva NA; Aĭlamazian EK; Baranov VS
Genetika; 2003 Apr; 39(4):525-9. PubMed ID: 12760253
[TBL] [Abstract][Full Text] [Related]
19. [Role of gene polymorphisms of phase II of xenobiotic biotransformation from glutathione-S-transferase and N-acetyltransferase families in susceptibility to lung cancer among Mayak workers].
Rusinova GG; Azizova TV; Viazovskaia NS; Glazkova IV; Gur'ianov MIu; Osovets SV
Radiats Biol Radioecol; 2014; 54(4):350-9. PubMed ID: 25775823
[TBL] [Abstract][Full Text] [Related]
20. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
